<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566289</url>
  </required_header>
  <id_info>
    <org_study_id>MIR-CIP 0004</org_study_id>
    <nct_id>NCT04566289</nct_id>
  </id_info>
  <brief_title>Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance</brief_title>
  <acronym>PiCSO-AMI-IV</acronym>
  <official_title>Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miracor Medical SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miracor Medical SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, single-arm, open label registry of commercially treated patients&#xD;
      with PiCSO Impulse System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a observational registry study. Patients with an ST-segment elevated anterior infarct&#xD;
      eligible for PCI and commercial PiCSO treatment will be invited to participate in the&#xD;
      PiCSO-AMI-IV study. After having given consent as per approved ethics committee requirements,&#xD;
      the PCI of the culprit vessel should be performed per standard practices. After blood flow&#xD;
      restoration, the coronary sinus (CS) will be cannulated through the femoral vein and the&#xD;
      PiCSO Impulse Catheter will be placed in the CS to start the PiCSO therapy. After the&#xD;
      procedure the patient will be followed for safety assessments at 30 days, 6 months, 1 year, 2&#xD;
      year and 3 years post index procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Adverse Device Effect (ADE) rate at 30 days post index procedure PCI</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse Device Effect (ADE) rate at 30 days post index procedure PCI</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">444</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Anterior MI</condition>
  <arm_group>
    <arm_group_label>PiCSO treatment group</arm_group_label>
    <description>PiCSO treatment as per IFU</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiCSO</intervention_name>
    <description>Percutaneous coronary intervention</description>
    <arm_group_label>PiCSO treatment group</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of subjects presenting with acute myocardial infarction,&#xD;
        pre-PCI TIMI flow 0 or 1 and symptom duration ≤ 12 h who are eligible for primary&#xD;
        percutaneous coronary intervention as per IFU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Culprit lesion in proximal or mid LAD&#xD;
&#xD;
          3. ST-segment elevation&#xD;
&#xD;
          4. Pre-PCI TIMI flow 0 or 1.&#xD;
&#xD;
          5. Symptoms onset time consistent with myocardial ischemia (e.g. persistent chest pain,&#xD;
             shortness of breath, nausea/vomiting, fatigue, palpitations or syncope) ≤ 12 h.&#xD;
&#xD;
          6. Patient is deemed eligible for PCI&#xD;
&#xD;
          7. Consent as per approved national ethical committee specific requirements prior to the&#xD;
             procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with contraindications to percutaneous insertion or angiography&#xD;
&#xD;
          2. Patients with implants or foreign bodies in the coronary sinus&#xD;
&#xD;
          3. Known allergy to polyurethanes, PET or stainless steel&#xD;
&#xD;
          4. Known pregnancy or breast feeding&#xD;
&#xD;
          5. Known pericardial effusion or cardiac tamponade&#xD;
&#xD;
          6. Known central hemodynamically relevant left/right shunt&#xD;
&#xD;
          7. Patients with symptom onset &gt; 12 hours&#xD;
&#xD;
          8. Patients with previous CABG&#xD;
&#xD;
          9. Patients with a history of stroke, TIA or reversible ischemic neurological deficit&#xD;
             within last 6 month.&#xD;
&#xD;
         10. Patients with coagulopathy&#xD;
&#xD;
         11. Patients under judicial protection, legal guardianship or curatorship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jozef Tanczos</last_name>
    <phone>+32 42 208 807</phone>
    <email>clinical@miracormedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herzzentrum Dresden GmbH Universitätsklinik an der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Axel Linke, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Al Qassimi</name>
      <address>
        <city>Sharjah</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <contact>
      <last_name>Arif Al Nooryani, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PiCSO</keyword>
  <keyword>PiCSO Impulse System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

